A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.

Start Date13 Feb 2020

Sponsor / Collaborator

AbbVie, Inc.

[+1]

NCT03243331 / CompletedPhase 1IIT

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer

Start Date19 Jan 2018

Sponsor / Collaborator

Indiana University

100 Clinical Results associated with PTK7 x Tubulin

100 Translational Medicine associated with PTK7 x Tubulin

0 Patents (Medical) associated with PTK7 x Tubulin

Literatures (Medical) associated with PTK7 x Tubulin

01 Sep 1998·Biological PsychiatryQ1 · MEDICINE

The role of the β-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms

Q1 · MEDICINE

Article

Author: Jacques Bradwejn ; Diana Koszycki ; François Bellavance ; Daniel Georges Bichet ; Jean-Michel Le Mellédo

BACKGROUNDThe authors determined whether effective beta-adrenergic blockade could attenuate the panicogenic effects of cholecystokinin-tetrapeptide (CCK-4) in healthy volunteers.METHODSSubjects were randomly assigned to either a propranolol (n = 14) or placebo (n = 16) infusion. Ten minutes after completion of the infusion subjects received a bolus injection of CCK-4 (50 micrograms).RESULTSAcute pretreatment with propranolol was more effective than placebo in decreasing behavioral and cardiovascular sensitivity.CONCLUSIONSThese preliminary results suggest that the panicogenic effects of CCK-4 are mediated, in part, through the beta-adrenergic system.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Who we are

Solutions
Plan
Contact us

What we do

Drug
Clinical Progress
Patent
Literature
Report
News